Treatment of acute schizophrenia with paliperidone ER: Predictors for treatment response and benzodiazepine use

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 207-212

  Heres, Stephan ^a   Don, Liana ^b   Herceg, Miroslav ^c   Bidzan, Leszek ^d   Blanc, Michel ^e   Siracusano, Alberto ^f   Maciulis, Valentinas ^g   Lahaye, Marjolein ^h   Schreiner, Andreas ⁱ  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Referentni centar za Alzheimerovu bolest i psihijatriju sta rijeivo t ne dobi   (Croatia)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e CHS Jury les Metz   (France)

^f TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^g Republican Vilnius Psychiatric Hospital   (Lithuania)

^h Janssen Cilag BV Netherlands   (Netherlands)

ⁱ JANSSEN CILAG GMBH   (Germany)

Author keywords

Acute schizophrenia; Benzodiazepine use; Clinical predictors; Paliperidone ER; Treatment response

Indexed keywords

BENZODIAZEPINE; BIPERIDEN; DIAZEPAM; LORAZEPAM; METOPROLOL; OLANZAPINE; PALIPERIDONE; PARACETAMOL; RISPERIDONE; TRIHEXYPHENIDYL; ZOLPIDEM; ZOPICLONE;

ACUTE DISEASE; ADULT; AGE; AGITATION; ANXIETY; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FUNCTIONAL ASSESSMENT; GENDER; HOSPITALIZATION; HUMAN; INSOMNIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PREDICTOR VARIABLE; PROSPECTIVE STUDY; PSYCHOSIS; RESTLESSNESS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE;

ACUTE SCHIZOPHRENIA; BENZODIAZEPINE USE; BMI; BODY MASS INDEX; CGI-S; CI; CLINICAL GLOBAL IMPRESSION-SEVERITY; CLINICAL PREDICTORS; CONFIDENCE INTERVAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, FOURTH EDITION; DSM-IV; ER; EXTENDED RELEASE; ODDS RATIO; OR; PALIPERIDONE ER; PALIPERIDONE ER TREATMENT IN ACUTE INTERVENTION; PANSS; PERSONAL AND SOCIAL PERFORMANCE; PERTAIN; POSITIVE AND NEGATIVE SYNDROME SCALE; PSP; SD; STANDARD DEVIATION; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886833150     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.09.015     Document Type: Article

References (32)

1. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003, 60:1228-1235.
2. Alphs L., Bossie C.A., Sliwa J.K., Ma Y.W., Turner N. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry 2011, 10:12.
3. American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders 1994, APA, Washington. 4th ed.
4. Awad A.G. Drug therapy in schizophrenia - variability of outcome and prediction of response. Can J Psychiatry 1989, 34:711-720.
5. Bartkó G., Frecska E., Horváth S., Zádor G., Arató M. Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients. Acta Psychiatr Scand 1990, 82:408-412.
6. Brousse G., Meary A., Blanc O., Lançon C., Llorca P.M., Leboyer M. Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia. Psychiatry Res 2010, 179:12-18.
7. Canuso C.M., Lindenmayer J.P., Kosik-Gonzalez C., Turkoz I., Carothers J., et al. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010, 71:587-598.
8. Change Y.C., Lane H.Y., Yang K.H., Huang C.L. Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol 2006, 26:554-559.
9. Chen L., Ascher-Svanum H., Stauffer V., Kinon B.J., Kollack-Walker S., Ruberg S. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res 2009, 113:34-40.
10. Crespo-Facorro B., Pelayo-Terán J.M., Pérez-Iglesias R., Ramírez-Bonilla M., Martínez-García O., et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res 2007, 41:659-666.
11. Davidson M., Emsley R., Kramer M., Ford L., Pan G., et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007, 93:117-130.
12. Emsley R., Oosthuizen P.P., Kidd M., Koen L., Niehaus D.J., Turner H.J. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006, 66:1707-1712.
13. Emsley R., Rabinowitz J., Medori R. Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007, 89:129-139.
14. Emsley R., Berwaerts J., Eerdekens M., Kramer M., Lane R., et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008, 23:343-356.
15. Guy W. Clinical global impressions. ECDEU assessment manual for psychopharmacology 1976, 218-222. US Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Rockville, MD.
16. Kane J.M., Leucht S., Carpenter D., Docherty J.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003, 64(Suppl. 12):20-51.
17. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
18. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008, 102:230-240.
19. Leucht S., Busch R., Kissling W., Kane J.M. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007, 68:352-360.
20. Leucht S., Sharmsi S.A., Busch R., Kissling W., Kane J.M. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr Res 2008, 101:312-319.
21. Levine S.Z., Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry 2010, 68:86-92.
22. Lin C.H., Chou L.S., Lin C.H., Hsu C.Y., Chen Y.S., Lane H.Y. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J Clin Psychiatry 2007, 88:1522-1527.
23. Lipkovich I.A., Deberdt W., Csernansky J.G., Buckley P., Peuskens J., et al. Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Res 2009, 170:161-167.
24. Meltzer H.Y., Bobo W.V., Nuamah I.F., Lane R., Hough D., et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008, 69:817-829.
25. Morosini P.L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101:323-329.
26. Nedopil N., Pflieger R., Rüther E. The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients. Pharmacopsychiatria 1983, 16:201-205.
27. Peuskens J., Bech P., Möller H.J., Bale R., Fleurot O., Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999, 88:107-117.
28. Rossi A., Bagalà A., Del Curatolo V., Scapati F., Bernareggi M.M., Giustra M.G. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol 2009, 24:574-583.
29. Schmauss M., Jukić V., Siracusano A., Bidzan L., Badescu G.M., et al. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study. Curr Med Res Opin 2012, 28:1395-1404.
30. Sechter D., Peuskens J., Fleurot O., Rein W., Lecrubier Y. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002, 27:1071-1081.
31. Semiz U.B., Cetin M., Basoglu C., Ebrinc S., Uzun O., Herken H., et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1330-1336.
32. Tabatabaee M., Sharifi V., Alaghband-rad J., Amini H., Boroumand M., et al. Acute treatment response and its predictors in patients with first-episode psychosis in Iran. Australas Psychiatry 2008, 16:125-129.